YOLFTbeta
Readgene

Readgene

RDG · WAR · Healthcare / Biotechnology

4.80PLN-0.04 (-0.83%)

Price History

Full chart

Market Stats

Previous Close4.84
Open4.72
Day Range4.72 – 4.80
52-Week Range4.57 – 6.32
Volume380
Market Cap41.97M
P/E (TTM)0.00
Forward P/E0.00
EPS0.0537
Dividend Yield0.00%
50-Day Avg0.00
200-Day Avg0.00

About

Read-Gene S.A. engages in the detection, prevention, and treating of various types of cancer in Poland. The company offers chemoprevention that uses natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer. It also provides clinical trials that involves evaluating whether a potential drug, product, or medical technology is effective and safe for the medical, pharmaceutical, chemical, and biotechnological industries. In addition, the company offers genetic tests; and advisory services for genetic counseling and support for oncological genetic counseling centers. Further, it operates an online platform for genetic tests and genetic-oncological consultations. The company was incorporated in 2005 and is based in Szczecin, Poland. Read-Gene S.A. operates as a subsidiary of Gen-Pat-Med Sp. z o.o.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jan Lubinski M.D., Ph.D.
  • Employees19
  • HeadquartersAkacjowa 2, Szczecin, Poland, Poland
  • Websitehttps://www.read-gene.com

Leadership

  • Dr. Jan Lubinski M.D., Ph.D.President of the Management Board · b. 1953
  • Dr. Karolina ErtmanskaFinancial Director
  • Slawomir SzymoniaAccountant

Financials

Income Statement

Currency: PLN2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.19M5.23M2.62M4.83M4.10M4.05M6.45M7.24M10.15M13.23M15.60M
Growth (%)-+139.06%-49.86%+84.43%-15.07%-1.33%+59.37%+12.20%+40.14%+30.38%+17.93%
Cost of Revenue2.03M2.56M2.19M2.70M3.65M1.56M703.79K1.06M1.02M889.79K1.00M
Gross Profit160.19K2.66M433.39K2.14M458.41K2.49M5.75M6.18M9.12M12.34M14.60M
Gross Margin7.33%50.95%16.54%44.22%11.17%61.43%89.10%85.41%89.91%93.27%93.56%
Operating Expense747.77K2.79M322.15K1.07M547.20K2.11M5.74M5.90M10.40M12.73M14.25M
Operating Income-587.58K-131.96K111.24K1.07M-88.79K378.60K13.81K286.27K-1.27M-390.74K352.31K
Operating Margin-26.88%-2.53%4.25%22.13%-2.16%9.35%0.21%3.95%-12.54%-2.95%2.26%
EBITDA---567.1966948.6821.6742.11K-732.68K236.00K899.56K
EBITDA Margin---0.01%0.02%0.02%0.01%10.25%-7.22%1.78%5.77%
Net Income-676.90K-493.89K-43.31K911.11K-76.53K226.35K37.88K213.23K-1.35M-1.11M96.84K
Net Income Margin-30.96%-9.45%-1.65%18.85%-1.86%5.59%0.59%2.94%-13.27%-8.40%0.62%
Interest Expense000133.73.1135.359.97K225.36K399.03K330.21K330.79K
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.93%3.11%3.93%2.50%2.12%

Balance Sheet

Currency: PLN2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets17.96M17.28M15.71M15.12M14.72M15.40M15.65M15.13M14.68M15.25M
Total Liabilities14.98M14.92M12.56M11.88M11.68M9.98M10.14M10.97M11.67M12.14M
Total Equity2.98M2.36M3.14M3.24M3.04M5.42M5.51M4.16M3.02M3.11M
Cash--5.015.847.027.06M7.18M5.65M5.52M5.17M
Total Debt262.87K420.78K--4.26M-----
Net Debt-------1.87M2.38M3.13M

Cash Flow

Currency: PLN2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-713.96K481.60K-340.03K-386.33K-2.49M1.07M106.26K347.90K-820.82K2.09M-123.49K
Investing Cash Flow-587.59K-407.68K--116.13K-147.65K-67.11K-----
Financing Cash Flow1.60M3.42M290.03K1.85M3.31M46.05K-----
Capital Expenditure587.59K407.68K00067.11K60.17K14.35K361.93K369.12K329.21K
Free Cash Flow-----987.58K46.09K333.55K-1.18M1.72M-452.70K
FCF to OCF-----92.18%43.37%95.88%144.09%82.35%366.58%

Earnings

Report DateJun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------------------------------------------------
EPS Actual0.020.00-0.01-0.010.000.00-0.03-0.00-0.00-0.01-0.04-0.02-0.00-0.01-0.000.000.00-0.02-0.04-0.020.04-0.040.050.01-0.02-0.040.12-0.03-0.05-0.040.20-0.05-0.07-0.070.250.00-0.040.020.040.000.01-0.050.07-0.030.03-0.01-0.00-0.04-0.06-0.030.01-0.05-0.030.02-0.04-0.010.02-0.020.100.06-0.04
Surprise-------------------------------------------------------------
Timing-------------------------------------------------------------

Key Statistics & Ratios

Market Cap41.97M
Enterprise Value0
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.00
EPS0.0537
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity1420.21%
Return on Assets0.00%
Shares Outstanding0
Shares Float0
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%